FDA Approves First Generic of ProAir HFA

The FDA approved Perrigo Pharmaceutical’s generic version of Teva’s ProAir HFA (albuterol sulfate) Inhalation Aerosol.

ProAir HFA is indicated to treat or prevent bronchospasm in patients four years of age and older with reversible obstructive airway disease, and to prevent exercise-induced bronchospasm.

FDA Commissioner Stephen Hahn said that the approval is part of the agency’s commitment to expand opportunities to bring generic copies of complex drugs to the market.